CLAIMS

1. Use of a compound represented by the following structural formula:



(I),

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a subject with acute myeloid leukemia or myelodysplastic syndrome, wherein:

the acute myeloid leukemia is relapsed or refractory.

2. The use according to claim 1, wherein the compound is a fumarate salt.

3. The use according to claim 2, wherein the molar ratio between the compound and fumaric acid is 1:1.

4. The use according to any one of claims 1-3, wherein the subject has acute myeloid leukemia.

5. The use according to any one of claims 1-4, wherein the acute myeloid leukemia is complex karyotype acute myeloid leukemia.

6. The use according to any one of claims 1-5, wherein an additional therapeutic agent is to be co-administered.

7. The use according to claim 6, wherein the additional therapeutic agent is an anti-cancer drug.

8. The use according to claim 7, wherein the anti-cancer drug is Venetoclax.

9. The use according to claim 7, wherein the anti-cancer drug is 5-Azacytidine.

10. The use according to any one of claims 6-9, wherein Compound (I) or a pharmaceutically acceptable salt thereof and the additional therapeutic agent are to be administered concurrently.

11. The use according to any one of claims 6-9, wherein Compound (I) or a pharmaceutically acceptable salt thereof and the additional therapeutic agent are to be administered sequentially.

12. The use according to claim 7, wherein the anti-cancer drug is decitabine.

13. Use of a compound represented by the following structural formula:



(I),

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a subject with acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma.

14. The use according to claim 13, wherein the compound is a fumarate salt.

15. The use according to claim 14, wherein the molar ratio between the compound and fumaric acid is 1:1.

16. The use according to any one of claims 13-15, wherein the subject has acute lymphoblastic leukemia.

17. The use according to claim 16, wherein the acute lymphoblastic leukemia is T-cell acute lymphoblastic leukemia or B-cell acute lymphoblastic leukemia.

18. The use according to any one of claims 13-15, wherein the subject has chronic myeloid leukemia.

19. The use according to any one of claims 13-15, wherein the subject has non-Hodgkin's lymphoma.

20. The use according to any one of claims 13-15, wherein the subject has Burkitt lymphoma.

21. The use according to any one of claims 13-15, wherein the subject has diffuse large B-cell lymphoma.

22. The use according to claim 21, wherein the diffuse large B-cell lymphoma is germinal center B cell-like or activated B cell-like.

23. The use according to any one of claims 13-22, wherein the acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma is relapsed or refractory.

24. The use according to any one of claims 13-23, wherein the acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma is complex karyotype.

25. The use according to any one of claims 13-24, wherein an additional therapeutic agent is to be co-administered.

26. The use according to claim 25, wherein the additional therapeutic agent is an anti-cancer drug.

27. The use according to claim 26, wherein the anti-cancer drug is Venetoclax, 5-Azacytidine, or decitabine.

28. The use according to any one of claims 25-27, wherein Compound (I) or a pharmaceutically acceptable salt thereof and the additional therapeutic agent are to be administered concurrently or sequentially.